Ligelizumab  (Synonyms: QGE 031; Anti-IGHE Recombinant Antibody)

Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma)^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IGHE

Ligelizumab is more effective than Omalizumab (HY-P9950) in blocking the binding of free IgE to FcεRI on plasmacytoid dendritic cells (pDCs)^[2].
In vitro, Ligelizumab can restore the ability of pDCs to produce IFN-α stimulated by TLR9-L, and the effect is better than Omalizumab^[2].
In in vitro co-culture experiments, Ligelizumab can restore the ability of pDCs to induce the generation of regulatory T cells (Tregs) like Omalizumab^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Ligelizumab (10 μg; intraperitoneal injection; single dose) can completely protect mice from antigen-induced systemic anaphylaxis in a human FcεRIα transgenic mouse passive systemic anaphylaxis model, and its effect on inhibiting IgE on the surface of mouse peritoneal mast cells is more significant than that of omalizumab (HY-P9950)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

P01854

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

146.32 kDa

1322627-61-1

Liquid

Colorless to light yellow

[Ligelizumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized IgE Fc Protein, Human can bind Ligelizumab. The EC₅₀ for this effect is 4.31 ng/mL.
• 
  Loaded Ligelizumab on AHC2 biosensor, can bind IgE Protein, Human (HEK293, His, HY-P73907) with an affinity constant of 1.089E-12 M as determined in BLI assay.

• [1]. Gasser P, et al. The mechanistic and functional profile of the therapeutic anti-IgE antibody ligelizumab differs from omalizumab. Nat Commun. 2020 Jan 8;11(1):165.  [Content Brief]

  [2]. Benito-Villalvilla C, et al. Ligelizumab impairs IgE-binding to plasmacytoid dendritic cells more potently than omalizumab and restores IFN-α production and FOXP3+ Treg generation. Allergy. 2023 Apr;78(4):1060-1072.  [Content Brief]